Molecular Excipient

342.0 -5.4 8 11 190.0 4 1.0
Present in 32 ZINC catalogs

Known Active Genes

There has not been any activity reported at 10μM or less for this excipient (per ChEBML)

Clinical Trials

This compound has been an intervention in the following clincial trials (per
Code Date Title Phase Status
NCT00888680 Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine Phase 2 Terminated
NCT02097706 2015-01-01 A Novel Cognitive Enhancing Drug for Borderline Personality Disorder Phase 4 Recruiting
NCT02117661 2015-01-01 Carnitine for the Treatment of Atherosclerosis. Phase 2 Recruiting
NCT02326350 2015-01-01 ASpirin as a Treatment for ARDS (STAR): a Phase 2 Randomised Control Trial Phase 2 Enrolling By Invitation
NCT01550107 2014-12-01 Allopurinol in Functional Impairment (ALFIE) Trial: 'Improving Muscle Strength' Phase 4 Enrolling By Invitation
NCT02097589 2014-06-01 The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23 Phase 4 Completed
NCT01644877 2014-03-01 A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen Phase 2 Recruiting
NCT02065076 2014-02-01 Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients Phase 4 Completed
NCT01675986 2014-01-01 Comparing the Efficacy of Pregabalin and Hydroxyzine on the Anxiety Score Phase 2 Recruiting
NCT02042521 2014-01-01 A Dietary Supplement for Early Cigarette Withdrawal Phase 2 Recruiting
NCT01986582 2013-10-01 NoAL (HPMC) in Combination With Oxymetazoline in Patients With Allergic Rhinitis Phase 2 Recruiting
NCT01748279 2012-12-01 The Effects of Atorvastatin Treatment in COPD Patients Phase 4 Completed
NCT01528800 2012-11-01 Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients Phase 2 Recruiting
NCT01659307 2012-09-01 The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury Phase 2 Recruiting
NCT01643187 2012-07-01 Comparison of the Effect of Two Treatments on the Nutritional and Micronutrient Status of Malnourished Children Phase 2 Not Yet Recruiting
NCT01602185 2012-05-01 Study of NMDA Antagonists and Neuropathic Pain Phase 2 Recruiting
NCT01536314 2012-02-01 Prophylaxis of Neuropathic Pain by mémantine Phase 3 Completed
NCT01575678 2012-01-01 The Effect of Melatonin on Nocturnal Enuresis Phase 2 Recruiting
NCT02214095 2012-01-01 Glucosamine Periodontal Adjunctive Therapy Phase 0 Terminated
NCT01504867 2012-01-01 LIPS-A: Lung Injury Prevention Study With Aspirin Phase 2 Recruiting
NCT01320345 2011-09-01 A Trial in Adults With Type 1 Diabetes Mellitus Evaluating the Effects of Fenofibrate Versus Placebo on Macular Thickness and Volume Phase 3 Not Yet Recruiting
NCT01400906 2011-07-01 Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics. Phase 2 Completed
NCT01404754 2011-03-01 Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers Phase 1 Enrolling By Invitation
NCT01127126 2010-12-01 Bryophyllum Versus Placebo for Overactive Bladder Phase 2 Completed
NCT01277237 2010-09-01 The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease Phase 3 Completed
NCT01190683 2010-08-01 Vitamin D and Muscle Strength and Surface (Electromyography) EMG Phase 3 Completed
NCT01113567 2010-07-01 Effect of Lactose in Patients With Chronic Liver Disease and Minimal Hepatic Encephalopathy Phase 3 Recruiting
NCT01098318 2010-06-01 Rhodiola Rosea Therapy of Major Depressive Disorder Phase 3 Completed
NCT01151306 2010-06-01 The Effect of Statins in Patients With Chronic Obstructive Pulmonary Disease (COPD) Phase 4 Completed
NCT01136317 2010-04-01 Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects Phase 2 Completed
NCT01040429 2010-02-01 The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial Phase 2 Completed
NCT01074554 2010-02-01 Trial of Antimycobacterial Therapy in Sarcoidosis Phase 1/Phase 2 Active, Not Recruiting
NCT01041755 2009-12-01 Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy. Phase 4 Completed
NCT01099332 2009-11-01 Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease Phase 1/Phase 2 Active, Not Recruiting
NCT01014338 2009-10-01 Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD) Phase 4 Completed
NCT00979056 2009-10-01 Prophylactic Treatment of Travellers' Diarrhoea With Rifaximin Phase 3 Completed
NCT00876161 2009-04-01 DAS181 Single Dose Escalation Study in Healthy Adults Phase 1 Completed
NCT00850460 2009-02-01 Quality of Life in Patients With Statin-Associated Myopathy Phase 4 Terminated
NCT00841230 2009-02-01 Deanxit and Rivotril in Tinnitus Patients Phase 4 Completed
NCT01269892 2009-01-01 Early Administration of Lactose-free Milk in Children Presenting With Acute Diarrhea Phase 2 Completed
NCT00755950 2008-10-01 Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis Phase 2/Phase 3 Terminated
NCT00682214 2008-05-01 Cholecalciferol Supplementation, Muscle Strength Phase 1 Completed
NCT00507000 2008-05-01 Pulmonary Tuberculosis and Vitamin D Phase 3 Active, Not Recruiting
NCT00624754 2008-03-01 Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT Phase 2 Completed
NCT00626275 2007-10-01 Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Subjects With Rheumatoid Arthritis Phase 2 Completed
NCT00403923 2007-04-01 Amount of Lactose Causing Symptoms in People With Lactose Intolerance and Ulcerative Colitis Phase 0 Completed
NCT00351117 2007-03-01 St. John's Wort in the Treatment of Raynaud's Phenomenon Phase 3 Completed
NCT00361543 2006-08-01 Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia Phase 4 Completed
NCT00504946 2005-09-01 Pharmacological Modulations of Allergen-Specific Immunotherapy Phase 3 Completed
NCT00149630 2005-01-01 Pharmacogenetics of Disulfiram for Cocaine Phase 2 Completed
NCT00090064 2004-03-01 A Test of MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder Phase 2 Completed
NCT02172508 2004-01-01 Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation Phase 4 Terminated
NCT00902616 2003-06-01 Effect of Arginine on Microcirculation in Patients With Diabetes Phase 4 Completed
NCT02175342 1998-03-01 Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD) Phase 2 Completed

(Browse) Purchasable Analogs in ZINC


Route Formulation Per Unit Dose
Buccal Tablet 21.38MG
Im - Iv Injection 1.25%
Im - Iv Powder 2.75%
Im - Iv Powder, For Injection Solution 2.5%
Im - Iv - Sc Powder, For Injection Solution, Lyophilized 10.7%
Im - Sc Injection 2.1%
Inhalation Powder, For Inhalation 62%
Intracavitary Powder, For Injection Solution, Lyophilized 4.54%
Intramuscular Injection 5%
Intramuscular Powder, For Injection Solution 10.7%
Intramuscular Powder, For Injection Solution, Lyophilized 1.05%
Intravenous Injection 4.5%W/V
Intravenous Injection 25%
Intravenous Powder, For Injection Solution 10.7%
Intravenous Powder, For Injection Solution 75%
Intravenous Powder, For Injection Solution, Lyophilized 69%
Iv - Sc Injection 4.9%
Iv(infusion) Injectable 4.5%W/V
Iv(infusion) Powder, For Injection Solution 20%
Iv(infusion) Powder, For Injection Solution, Lyophilized 4.75%W/V
Iv(infusion) Powder, For Injection Suspension, Lyophilized 10.2%W/V
Oral Capsule 427.26MG
Oral Capsule 430.42MG
Oral Capsule (immed./comp. Release) 112MG
Oral Capsule (immed./comp. Release), Hard Gelatin 166.77MG
Oral Capsule, Coated Pellets 33.09MG
Oral Capsule, Coated, Hard Gelatin 85MG
Oral Capsule, Coated, Soft Gelatin 178.91MG
Oral Capsule, Delayed Action 125.09MG
Oral Capsule, Delayed Action, Enteric Coated, Hard Gelatin 76.4MG
Oral Capsule, Enteric Coated Pellets 100MG
Oral Capsule, Extended Release 536.4MG
Oral Capsule, Hard Gelatin 199.5MG
Oral Capsule, Hard Gelatin 141MG
Oral Capsule, Sustained Action 67MG
Oral Capsule, Sustained Action 147.6MG
Oral Capsule, Sustained Action, Hard Gelatin 18.8MG
Oral Dispersible Tablet 543.6MG
Oral Granule 109.8MG
Oral Granule, For Suspension
Oral Powder, For Inhalation 2.5%
Oral Powder, For Suspension
Oral Tablet 180MG
Oral Tablet 696.3MG
Oral Tablet 708.9MG
Oral Tablet 455MG
Oral Tablet (immed./comp. Release), Coated 254MG
Oral Tablet (immed./comp. Release), Film Coated 269.8MG
Oral Tablet (immed./comp. Release), Uncoated, Chewable 62.3MG
Oral Tablet (immed./comp. Release), Uncoated, Chewable 100MG
Oral Tablet, Chewable 98.67MG
Oral Tablet, Coated 346.5MG
Oral Tablet, Coated 186MG
Oral Tablet, Controlled Release 152.75MG
Oral Tablet, Delayed Action 385.55MG
Oral Tablet, Delayed Action, Enteric Coated 157.95MG
Oral Tablet, Delayed Action, Enteric Coated 88.5MG
Oral Tablet, Delayed Release 30MG
Oral Tablet, Enteric Coated Particles 150MG
Oral Tablet, Extended Release 538MG
Oral Tablet, Extended Release 43.23MG
Oral Tablet, Film Coated 587.44MG
Oral Tablet, Film Coated 556MG
Oral Tablet, For Suspension 4.9MG
Oral Tablet, Multilayer, Coated 22.7MG
Oral Tablet, Orally Disintegrating 145.2MG
Oral Tablet, Repeat Action 155.28MG
Oral Tablet, Sustained Action 299.2MG
Oral Tablet, Sustained Action 156.8MG
Oral Tablet, Sustained Action, Coated 215MG
Oral Tablet, Sustained Action, Coated 83.3MG
Oral Tablet, Sustained Action, Film Coated 260MG
Oral Tablet, Sustained Release, Film Coated 81.9MG
Oral-21 Tablet 83.65MG
Oral-21 Tablet 48MG
Oral-21 Tablet, Coated 35.19MG
Oral-28 Tablet 93.87MG
Oral-28 Tablet 39.62MG
Oral-28 Tablet, Coated 82.89MG
Oral-28 Tablet, Film Coated 65.37MG
Respiratory (inhalation) Powder, For Inhalation 2%
Subcutaneous Powder, For Injection Solution 10.7%
Sublingual Tablet 191.76MG
Sublingual Tablet 164.38MG
Sublingual Tablet (immed./comp. Release), Uncoated, Buccal 160.4MG
Vaginal Emulsion, Cream
Vaginal Insert 760.5MG
Vaginal Tablet 760.5MG
Vaginal Tablet 596MG
Vaginal Tablet, Film Coated 17.9MG

More Information

Usage Over Time